HENDERSON, NV / ACCESSWIRE / October 4, 2018 / At the risk of stating the obvious, investing is about finding undervalued companies. I feel the need to emphasize this basic truth because in the rush for hopping on the next hype train this is sometimes ignored in the name of 'potential'. Huge potential can certainly lead to some major profits, but one sure way to pad your portfolio with gains is investing in fundamentally undervalued companies before the crowd.
That's why we're excited to highlight Dyadic International, Inc. (DYAI). DYAI has over $40 million in the bank, a stock buyback agreement, and entered into an additional fully funded research collaboration with Sanofi-Aventis to test the feasibility of using C1 to produce multiple genes for vaccine and drug applications. For those that do not know Sanofi-Aventis is over a $100 Billion company that trades on the New York Stock Exchange. So for DYAI to be collaborating with them is a huge feather in the cap of DYAI. DYAI currently has assets on its balance sheet of over $49 Million while only has a market cap of $46 Million. This feels like a massive opportunity for anyone that finds out about DYAI before the public at large.
DYAI stock trades at less than $2 while I write this, however, they are presenting in front of a large group of street investors later this week so that could change VERY quickly.
DYAI is focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales. Look at some of the major milestones they’ve recently hit:
- Indicated C1 can express a variety of different types of vaccines and therapeutic proteins, including monoclonal antibodies (mAbs), Fab antibody fragments, FC-Fusion proteins, and difficult-to-express genes such, as virus-like particles (VLPs), Bi-Specific antibodies, and antigens, at a higher productivity level than other gene expression platforms.
- Entered into an additional research collaboration with a biotech company to test the feasibility of using C1 to produce seven different molecular biology enzymes as pharmaceutical products. The company secured a total of four collaborations since the beginning of this year
- Achieved record C1 productivity levels as high as 2.4 grams per liter per day (9 g/l in 90 hours) for monoclonal antibodies and 1.9 grams per liter per day for Fabs.
- Acheived 50% C1 fermentation process improvement accompanied by a corresponding drop in the defined media cost.
- Created C1 protease expression library and improved protein stability and productivity by eliminating targeted C1 protease genes.
Once again, this company is presenting at a major conference this week, so it would be wise to act now on this undervalued opportunity.
Dyadic International, Inc. (DYAI)
Market Cap: $47.81M Share Price: $1.79
Dyadic International, Inc. (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, will present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX® Virtual Investor Conference featuring US-based issuers traded on the OTCQX Best Market. This will get the company a ton of exposure, so it may be wise to beat the crowd on this one.
vTv Therapeutics, Inc. (VTVT)
Market Cap: $165.33M Share Price: $4.42
VTVT recently reported its second quarter results. The company reported loss of $0.29 per share for the quarter, which trailed behind the consensus estimates of loss per share of $0.25 by $0.04. vTv Therapeutics reported revenue of $2.47 million, while analysts had expected revenue of $2.46 million. It was revealed at the end of last month that major shareholder Ronald O. Perelman had acquired 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 6th. The company discovers, develops, and sells orally administered small molecule drug candidates worldwide and has a drug candidate called azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Aurora Cannabis, Inc. (ACBFF)
Market Cap: $8.9B Share Price: $9.35
Micron Waste Technologies Inc. reported positive results from the optimization of the Cannavore™ cannabis waste processing units with Aurora Cannabis Inc.. The Company will now optimize the technology for sub-zero operations, as well as add computerized remote operating capabilities, following which Micron will commence to offer the units commercially.
GW Pharmaceuticals plc (GWPH)
Market Cap: $4.60B Share Price: $162.90
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, just announced the pricing of an underwritten public offering by the Company. GW will issue 1,900,000 American Depositary Shares, representing 22,800,000 ordinary shares of GW, at a price to the public of $158.00 per ADS on the Nasdaq Global Market, raising gross proceeds of approximately $300 million (before deducting underwriting discounts, commissions and offering expenses). GW granted the underwriters a 30-day option to purchase up to an additional 285,000 ADSs at the public offering price less underwriting discounts and commissions. Closing of the offering is expected to occur on October 5th , 2018.
Pain Therapeutics, Inc. (PTIE)
Market Cap: $29.95M Share Price: $1.75
Pain Therapeutics, Inc., a biopharmaceutical company, announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and one thousand dollars total by Regal Consulting. LLC, for news commentary articles for DYAI. DYAI and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of DYAI in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC,For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications, LLC